Get the Stockscreener App
12.58
0.72%
0.09
After Hours:
12.58
Ars Pharmaceuticals Inc stock is traded at $12.58, with a volume of 1.78M.
It is up +0.72% in the last 24 hours and up +20.04% over the past month.
See More
Previous Close:
$12.49
Open:
$12.1
24h Volume:
1.78M
Relative Volume:
1.17
Market Cap:
$1.26B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-26.77
EPS:
-0.47
Net Cash Flow:
$-44.23M
1W Performance:
-2.40%
1M Performance:
+20.04%
6M Performance:
-13.24%
1Y Performance:
+23.09%
1-Day Range:
$11.85
$12.77
1-Week Range:
$11.85
$13.22
52-Week Range:
$7.55
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
12.58 | 1.26B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term - simplywall.st
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year - Yahoo Finance
Long Term Trading Analysis for (SPRY) - Stock Traders Daily
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript - MSN
Raymond James lifts ARS Pharmaceuticals price target to $32 - Investing.com
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
Neffy 1 mg Approved to Treat Severe Allergic Reactions in Younger Children - Pulmonology Advisor
ARS Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - MSN
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock - Investing.com Australia
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock By Investing.com - Investing.com South Africa
neffy From ARS Pharmaceuticals, Inc - Pharmacy Times
ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates - MSN
Decoding ARS Pharmaceuticals Inc (SPRY): A Strategic SWOT Insigh - GuruFocus
ARS Pharmaceuticals Reports Strong 2024 Financial Results - TipRanks
Raymond James maintains $28 target on ARS Pharma stock By Investing.com - Investing.com South Africa
ARS Pharmaceuticals: Surging On Solid EarningsBut Real Challenges Await (NASDAQ:SPRY) - Seeking Alpha
Raymond James maintains $28 target on ARS Pharma stock - Investing.com India
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. - MSN
Earnings call transcript: ARS Pharmaceuticals Q4 2024 earnings beat expectations - Investing.com
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
ARS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sector Update: Health Care Stocks Decline Pre-Bell Thursday - TradingView
Sector Update: Health Care - TradingView
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
ARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings -March 20, 2025 at 07:45 am EDT - MarketScreener
ARS PHARMACEUTICALS Earnings Results: $SPRY Reports Quarterly Earnings - Nasdaq
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Revenue $86.6M -March 20, 2025 at 07:13 am EDT - Marketscreener.com
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 EPS $0.48, vs. FactSet Est of $-0.04 Loss - Marketscreener.com
ARS Pharmaceuticals, Inc. SEC 10-K Report - TradingView
ARS Pharma Crushes Q4 with $49.9M Profit as Neffy Launch Gains Momentum - StockTitan
This company’s epinephrine nasal spray reverses allergic reactions—no needle required - Fast Company
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Fast Company
(SPRY) Investment Report - Stock Traders Daily
Steward Partners Investment Advisory LLC Raises Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on Thursday - Defense World
Scotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY) - Defense World
Scotiabank Initiates Coverage of ARS Pharmaceuticals (SPRY) with Sector Outperform Recommendation - Nasdaq
Rhumbline Advisers Buys 1,824 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Ars pharmaceuticals director Laura Shawver sells $560,445 in stock By Investing.com - Investing.com Canada
US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients - Reuters
San Diego biotech gets FDA approval for EpiPen alternative for kids - MSN
Exploring High Growth Tech Stocks in the US Market - Simply Wall St
California biotech company gets FDA approval for EpiPen alternative for kids - East Bay Times
Scotiabank sets $30 target for ARS Pharmaceuticals stock - Investing.com
Scotiabank sets $30 target for ARS Pharmaceuticals stock By Investing.com - Investing.com Canada
FDA Approves ARS Pharmaceuticals’ neffy for Type 1 Allergic Reactions in Pediatric Patients - Pharmaceutical Executive
FDA Approves Low-Dose Neffy Epinephrine Spray for Young Kids - Allergic Living
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):